arrow
V

Verena Keitel

Otto-Von-Guericke University
H指数:55
被引数:1.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Update of the S3 Guideline "Rare Liver Diseases (LeiSe LebEr) - Autoimmune Liver Diseases from Pediatrics to Adulthood" of the German Society for Gastroenterology, Digestive and Metabolic Diseases (DGVS) - Living Guideline October 2025-Version 3.0-AWMF Registry Number: 021-027

德国胃肠病学、消化与代谢疾病学会(DGVS)S3指南《罕见肝病(LeiSe LebEr)——从儿科到成人的自身免疫性肝病》更新 - 动态指南 2025年10月 版本3.0 - AWMF注册号:021-027

2026-05-011
PRE
CAR T-cell therapy induces remission in multiorgan IgG4-related disease with hepatobiliary involvement

CAR T-cell疗法可诱导伴有肝胆系统受累的多器官IgG4相关疾病的缓解。

2025-12-080
OAAI
Real-world-data on efficacy and safety of topical budesonide therapy (orodispersible tablet) in induction and maintenance therapy in adult patients with active eosinophilic esophagitis

关于奥洛夫可分散片(Orodispersible tablet)局部布地奈德疗法在成人活动性嗜酸性食管炎患者诱导及维持治疗中的疗效和安全性的真实世界数据

2025-10-080
OA
Radiomics-based prediction of HCC response to atezolizumab/bevacizumab

基于放射组学的预测HCC对阿替利珠单抗/贝伐珠单抗的应答

2025-10-010
OAAI
A Farnesoid X Receptor T296I Variant Disrupts Ligand-induced FXR Activation and thus Bile Acid Transport in Progressive Familial Intrahepatic Cholestasis

法尼醇X受体T296I变异体破坏了配体诱导的FXR激活,进而影响进行性家族性肝内胆汁淤积症中的胆汁酸转运。

2025-09-290
OAAI
Genetic and clinical risk factors for anti-tuberculosis drug-induced liver injury: insights from a prospective cohort study in central Ethiopia

抗结核药物诱导性肝损伤的遗传和临床危险因素:来自埃塞俄比亚中部前瞻性队列研究的启示

2025-09-040
OAAI
The history and future of bile acid therapies

Beuers, U.; Banales, J.M.; Karpen, S.; Keitel, V.; Williamson, C.; Trauner, M. 胆汁酸疗法的历史与展望. J. Hepatol. 2025; 已接收. [Google Scholar] [CrossRef]

2025-06-200
PRE